Taking resM on an empty stomach is unlikely to cause harm but may reduce the immediate blood sugar benefits
Im grateful to have worked with a fantastic study team and collaborators on this important question
Instead, its about leveraging continuous glucose monitors, evaluating new data on GLP-1 receptor agonists, and integrating behavioral coaching into the treatment plan
Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9)
Atul Malhotra, MD, a sleep medicine specialist at UC San Diego Health, and co-authors conducted two phase 3, double-blind, randomized controlled trials for tirzepatide in moderate-to-severe OSA patients with obesity who were and were not using CPAP
For many patients, retatrutide is of particular interest because the active ingredient has been associated with substantial weight reduction in clinical trials